Correlation of DNA Methylation and Hormone Receptor Status in Breast Cancer
Author Information
Author(s): Feng Weiwei, Shen Lanlan, Wen Sijin, Rosen Daniel G, Jelinek Jaroslav, Hu Xin, Huan Shaoyi, Huang Miao, Liu Jinsong, Sahin Aysegul A, Hunt Kelly K, Bast Robert C Jr, Shen Yu, Issa Jean-Pierre J, Yu Yinhua
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
Does the methylation of growth-suppressor genes correlate with the expression of estrogen and progesterone receptors in breast cancer?
Conclusion
The study identified two panels of methylation profiles that correlate with hormone receptor status in breast cancer.
Supporting Evidence
- Five genes were frequently methylated in breast cancers but not in normal breast tissues.
- Methylation of the HIN-1/RASSF1A panel correlated with positive hormone receptor expression.
- Methylation of the RIL/CDH13 panel correlated with negative hormone receptor expression.
- 11% of tumors had p53 mutations, mostly in the methylation-negative group.
- Triple-negative breast cancers were positively associated with the RIL/CDH13 panel methylation.
Takeaway
The study looked at how certain genes are turned off in breast cancer and found that this is linked to whether the cancer responds to hormones.
Methodology
The study used pyrosequencing to analyze the methylation of 12 tumor-suppressor genes in paired breast cancer and normal tissues.
Limitations
The study did not have sufficient survival data to correlate methylation to prognosis.
Participant Demographics
Median age of participants was 57 years, with a range from 29 to 81 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website